Epidemiology and Clinical Course of Chronic Autoimmune Neuropathies During the SARS-CoV-2 Pandemic in Latvia

Q4 Medicine
Ieva Glāzere, Marija Luīze Kalniņa, Dmitrijs Rots, Marija Roddate, Linda Gailīte, Nataļja Kurjāne, Viktorija Ķēniņa
{"title":"Epidemiology and Clinical Course of Chronic Autoimmune Neuropathies During the SARS-CoV-2 Pandemic in Latvia","authors":"Ieva Glāzere, Marija Luīze Kalniņa, Dmitrijs Rots, Marija Roddate, Linda Gailīte, Nataļja Kurjāne, Viktorija Ķēniņa","doi":"10.2174/1874205x-v17-230619-2022-14","DOIUrl":null,"url":null,"abstract":"Background: Chronic autoimmune neuropathies are a group of rare neurological disorders caused by the immune response to autoantigens in the peripheral nervous system. Objective: This study aimed to report epidemiological data in Latvia on the most common chronic autoimmune neuropathies and evaluate SARS-CoV-2 infections or vaccinations’ impact on our patient’s clinical course of the disease. Methods: A single-center observational study was performed, which included all patients diagnosed with chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN) in Latvia since 2015. Prevalence and incidence were calculated by using population data from the corresponding time of the Central Statistics Bureau of Latvia. Detailed clinical evaluation and re-assessment of diagnostic criteria were performed in the whole study group. All patients underwent telephone interviews regarding their SARS-CoV-2 vaccination or infection status. Results: This study included 23 CIDP and 8 MMN patients. The point prevalence and incidence of CIDP were 1.21 per 100 000 people and 1.16 per 100 000 people, respectively. The point prevalence and incidence of MMN were 0.42 per 100 000 individuals and 0.40 per 100 000 individuals, respectively. Most of the patients involved in this study (90%, n=28) with CIDP or MMN were vaccinated against SARS-CoV-2 infection, and none of the patients experienced fluctuations or relapse regarding autoimmune polyneuropathy. Conclusion: The incidence and prevalence of CIDP and MMN in Latvia are similar to previously reported European studies. In our study group, vaccination against SARS-CoV-2 was safe and did not negatively affect the clinical course of CIDP and MMN patients.","PeriodicalId":39123,"journal":{"name":"Open Neurology Journal","volume":"127 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Neurology Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1874205x-v17-230619-2022-14","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Chronic autoimmune neuropathies are a group of rare neurological disorders caused by the immune response to autoantigens in the peripheral nervous system. Objective: This study aimed to report epidemiological data in Latvia on the most common chronic autoimmune neuropathies and evaluate SARS-CoV-2 infections or vaccinations’ impact on our patient’s clinical course of the disease. Methods: A single-center observational study was performed, which included all patients diagnosed with chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN) in Latvia since 2015. Prevalence and incidence were calculated by using population data from the corresponding time of the Central Statistics Bureau of Latvia. Detailed clinical evaluation and re-assessment of diagnostic criteria were performed in the whole study group. All patients underwent telephone interviews regarding their SARS-CoV-2 vaccination or infection status. Results: This study included 23 CIDP and 8 MMN patients. The point prevalence and incidence of CIDP were 1.21 per 100 000 people and 1.16 per 100 000 people, respectively. The point prevalence and incidence of MMN were 0.42 per 100 000 individuals and 0.40 per 100 000 individuals, respectively. Most of the patients involved in this study (90%, n=28) with CIDP or MMN were vaccinated against SARS-CoV-2 infection, and none of the patients experienced fluctuations or relapse regarding autoimmune polyneuropathy. Conclusion: The incidence and prevalence of CIDP and MMN in Latvia are similar to previously reported European studies. In our study group, vaccination against SARS-CoV-2 was safe and did not negatively affect the clinical course of CIDP and MMN patients.
拉脱维亚SARS-CoV-2大流行期间慢性自身免疫性神经病变的流行病学和临床病程
背景:慢性自身免疫性神经病是由周围神经系统对自身抗原的免疫反应引起的一组罕见的神经系统疾病。目的:本研究旨在报告拉脱维亚最常见的慢性自身免疫性神经病变的流行病学数据,并评估SARS-CoV-2感染或疫苗接种对患者临床病程的影响。方法:采用单中心观察性研究,纳入拉脱维亚2015年以来诊断为慢性炎症性脱髓鞘性多神经病变(CIDP)和多灶性运动神经病变(MMN)的所有患者。患病率和发病率是利用拉脱维亚中央统计局相应时间的人口数据计算的。在整个研究组中进行详细的临床评估和诊断标准的重新评估。所有患者都接受了关于其SARS-CoV-2疫苗接种或感染状况的电话访谈。结果:本研究纳入23例CIDP和8例MMN患者。点患病率和发病率分别为1.21 / 10万人和1.16 / 10万人。MMN的点患病率和发病率分别为0.42 / 10万和0.40 / 10万。本研究涉及的大多数CIDP或MMN患者(90%,n=28)接种了SARS-CoV-2感染疫苗,没有患者出现自身免疫性多神经病变的波动或复发。结论:拉脱维亚的CIDP和MMN的发病率和流行程度与先前报道的欧洲研究相似。在我们的研究组中,接种SARS-CoV-2疫苗是安全的,并且对CIDP和MMN患者的临床病程没有负面影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Open Neurology Journal
Open Neurology Journal Medicine-Psychiatry and Mental Health
CiteScore
0.30
自引率
0.00%
发文量
11
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信